Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' Equity/(Deficit)

v3.22.1
Consolidated Statement of Changes in Stockholders' Equity/(Deficit) - USD ($)
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Common stock No Par Value [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 3,806 $ 36,848,063 $ (39,184,699) $ (2,332,830)
Beginning balance, shares at Dec. 31, 2019   27,785,366      
Net loss (9,487,824) (9,487,824)
Private placement of common shares $ 198 1,979,802 1,980,000
Private placement of common shares, shares     767,941      
Modification of the terms of 4,188,315 MyMD stock options 2,009,145 2,009,145
Stock-based compensation for borrowings 1,719,477 1,719,477
Stock-based compensation 855,000 855,000
Ending balance, value at Dec. 31, 2020 $ 4,004 43,411,487 (48,672,523) (5,257,032)
Ending balance, shares at Dec. 31, 2020   28,553,307      
Net loss (29,889,045) (29,889,045)
Reverse merger with Akers Biosciences Inc effective April 16, 2021 $ 144,524 42,332,834 42,477,358
Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares 72,992   8,335,627      
Issuance of post-merger MyMD Pharmaceutical Inc common shares at an exchange ratio of 0.7718 per pre-merger MyMD common share 43,415,491 $ (4,004) (43,411,487)
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement 15,036,051 15,036,051
Exercise of per-merger MyMD stock options
Exercise of per-merger MyMD stock options, shares     11,576     11,576
Exercise of prepaid equity forward contracts for common stock
Exercise of prepaid equity forward contracts for common stock, shares     466,716      
Stock based compensation for services 90,002 90,002
Stock based compensation for services, shares     16,826      
Exercise of warrants for common stock 1,189,840 1,189,840
Exercise of warrants for common stock, shares     289,058      
Ending balance, value at Dec. 31, 2021 $ 144,524 $ 102,064,218 $ (78,561,568) $ 23,647,174
Ending balance, shares at Dec. 31, 2021 72,992   37,673,110